Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

iDD Biotech (antibody assets)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Antibody therapeutics for the treatment of cancer. The monoclonal antibodies (mAb or moAb) are monospecific antibodies that are made by identical immune cells that are all clones of a unique parent cell, in contrast to polyclonal antibodies which are made from several different immune cells.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Bâtiment Accinov
  • 317 avenue Jean Jaurès
  • 69007 Lyon
  • France

+33 04 00 00 00 00

iDD Biotech (antibody assets) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore iDD Biotech (antibody assets)‘s full profile, request access.

Request full access to PitchBook

iDD Biotech (antibody assets) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore iDD Biotech (antibody assets)‘s full profile, request access.

Request full access to PitchBook